MATRA-A: A study on massive transfusion.
Turkey
indications
massive transfusion
mortality
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
18
01
2021
received:
26
08
2020
accepted:
18
01
2021
pubmed:
27
2
2021
medline:
16
10
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
We use massive transfusion in various clinical conditions and it is associated with high mortality. Although some massive transfusion protocols improve patient outcomes, the clinical circumstances requiring it are not well defined. MATRA-A is a multicenter retrospective study. Six University and Training Research Hospitals in Ankara participated in the study. We collected clinical data on patients (>18 years) who received massive transfusions (≥10 units/24 h) from 2017 through 2019. Overall, 167 (0·27% of transfused patients) received a massive transfusion of 2586 units of red blood cells (1·5% of total RBCs transfused). The median interquartile range values for RBCs, fresh frozen plasma (FFP) and platelets were 13 (11-176), 16 (9-33) and 4 (0-11), respectively. Surgical patients received 90% of massive transfusions. The most common clinical indications for massive transfusion were cardiovascular diseases (42·6%), trauma (20·3%) and malignancies (11%). FFP: RBC: Platelets ratio was 1·9:1:0·5. The overall and trauma-related mortality rates were 57·4% and 61·8%, respectively. The hospital mortality rates of trauma patients that received high vs. low ratio (FFP: RBCs > 1:1·5 vs. ≤1:1·5) transfusions were 47·6% and 86·6% and the difference was statistically significant (P = 0·03). Cardiovascular diseases and trauma occasion are the most common causes of massive transfusion. It is infrequent in clinical settings and is associated with high mortality rates. Additionally, in massively transfused trauma patients, a high FFP:RBCs ratio seems to be associated with increased survival. Focused prospective studies are required to define the areas that need improvement on a national scale.
Sections du résumé
BACKGROUND
BACKGROUND
We use massive transfusion in various clinical conditions and it is associated with high mortality. Although some massive transfusion protocols improve patient outcomes, the clinical circumstances requiring it are not well defined.
METHODS
METHODS
MATRA-A is a multicenter retrospective study. Six University and Training Research Hospitals in Ankara participated in the study. We collected clinical data on patients (>18 years) who received massive transfusions (≥10 units/24 h) from 2017 through 2019.
RESULTS
RESULTS
Overall, 167 (0·27% of transfused patients) received a massive transfusion of 2586 units of red blood cells (1·5% of total RBCs transfused). The median interquartile range values for RBCs, fresh frozen plasma (FFP) and platelets were 13 (11-176), 16 (9-33) and 4 (0-11), respectively. Surgical patients received 90% of massive transfusions. The most common clinical indications for massive transfusion were cardiovascular diseases (42·6%), trauma (20·3%) and malignancies (11%). FFP: RBC: Platelets ratio was 1·9:1:0·5. The overall and trauma-related mortality rates were 57·4% and 61·8%, respectively. The hospital mortality rates of trauma patients that received high vs. low ratio (FFP: RBCs > 1:1·5 vs. ≤1:1·5) transfusions were 47·6% and 86·6% and the difference was statistically significant (P = 0·03).
CONCLUSION
CONCLUSIONS
Cardiovascular diseases and trauma occasion are the most common causes of massive transfusion. It is infrequent in clinical settings and is associated with high mortality rates. Additionally, in massively transfused trauma patients, a high FFP:RBCs ratio seems to be associated with increased survival. Focused prospective studies are required to define the areas that need improvement on a national scale.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-886Informations de copyright
© 2021 International Society of Blood Transfusion.
Références
Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg 2012;73:S431-7.
Ruseckaite R, McQuilten ZK, Oldroyd JC, et al. Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. Vox Sang 2017;112:240-8.
Patient Blood Management Guidelines: Module 1 Critical Bleeding/Massive Transfusion, 2011. https://www.blood.gov.au/pbm-module-1 [Accessed March, 2020].
Cantle PM, Cotton BA. Prediction of massive transfusion in trauma. Crit Care Clin 2017;33:71-84.
Nunez TC, Voskresensky IV, Dossett LA, et al. Early prediction of massive transfusion in trauma: simple as ABC (Assessment of blood consumption)? J Trauma 2009;66:346-52.
Kautza BC, Cohen MJ, Cuschieri J, et al. Changes in massive transfusion over time: an early shift in the right direction? J Trauma Acute Care Surg 2012;72:106-11.
Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471-82.
Stephens CT, Gumbert S, Holcomb JB. Trauma-associated bleeding: management of massive transfusion. Curr Opin Anaesthesiol 2016;29:250-5.
Abuzeid AM, O'Keeffe T. Review of massive transfusion protocols in the injured, bleeding patient. Curr Opin Crit Care 2019;25:661-7.
Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019;23:98.
Sawyer PR, Harrison CR. Massive transfusion in adults. Diagnoses, survival and blood bank support. Vox Sang 1990;58:199-203.
Zatta AJ, McQuilten ZK, Mitra B, et al. Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion. Vox Sang 2014;107:60-70.
Johnson DJ, Scott AV, Barodka VM, et al. Morbidity and mortality after high-dose transfusion. Anesthesiology 2016;124:387-95.
Sommer N, Schnuriger B, Candinas D, et al. Massive transfusion protocols in nontrauma patients: a systematic review and meta-analysis. J Trauma Acute Care Surg 2019;86:493-504.
Dzik WS, Ziman A, Cohn C, et al. Survival after ultramassive transfusion: a review of 1360 cases. Transfusion 2016;56:558-63.
Flint AWJ, McQuilten ZK, Wood EM. Massive transfusions for critical bleeding: is everything old new again? Transfus Med 2018;28:140-49.
Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma 2009;66:41-8; discussion 8-9.
Seghatchian J, Samama MM. Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy. Transfus Apher Sci 2012;47:235-43.
Technical Assistance for Improving the Blood Transfusion Management System in Turkey, 2019. https://hastakanyonetimi.saglik.gov.tr/Content/Index/?id=2 [Accessed May, 2020].
Halmin M, Chiesa F, Vasan SK, et al. Epidemiology of massive transfusion: a binational study from Sweden and Denmark. Crit Care Med 2016;44:468-77.
Peralta R, Vijay A, El-Menyar A, et al. Trauma resuscitation requiring massive transfusion: a descriptive analysis of the role of ratio and time. World J Emerg Surg 2015;10:36.
Doughty H, Apelseth TO, Sivertsen J, et al. Massive transfusion: changing practice in a single Norwegian centre 2002-2015. Transfus Med 2018;28:357-62.
Mitra B, Cameron PA, Gruen RL, et al. The definition of massive transfusion in trauma: a critical variable in examining evidence for resuscitation. Eur J Emerg Med 2011;18:137-42.
Green L, Tan J, Grist C, et al. Aetiology and outcome of massive transfusion in two large London teaching hospitals over a 3-year period (2012-2014). Transfus Med 2017;27(Suppl 5):342-7.
Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006;34:1608-16.
Delaney M, Stark PC, Suh M, et al. Massive transfusion in cardiac surgery: the impact of blood component ratios on clinical outcomes and survival. Anesth Analg 2017;124:1777-82.
Morse BC, Dente CJ, Hodgman EI, et al. Outcomes after massive transfusion in nontrauma patients in the era of damage control resuscitation. Am Surg 2012;78:679-84.
Pham HP, Shaz BH. Update on massive transfusion. Br J Anaesth 2013;111(Suppl 1):i71-82.
Eksert S, Unlu A, Aydin FN, et al. Analysis of anatomical localization and severity of injury in patients with blood transfusion in Urban Terrain Hospital. Ulus Travma Acil Cerrahi Derg 2020;26:937-42.
Ramsey G. Blood component transfusions in mass casualty events. Vox Sang 2017;112:648-59.
Ramsey G. Blood transfusions in mass casualty events: recent trends. Vox Sang 2020;115:358-66.
Gunter OL Jr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma 2008;65:527-34.
Lustenberger T, Frischknecht A, Brüesch M, et al. Blood component ratios in massively transfused, blunt trauma patients-a time-dependent covariate analysis. J Trauma 2011;71(5):1144-51; discussion 50-1.
Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
Murthy T. Blood transfusion practices in sepsis. Indian J Anaesth 2014;58:643-6.
Tupchong KKA, Foran M. Sepsis, severe sepsis, and septic shock: A review of the literature. Afr J Emerg Med 2015;5:127-35.